Suppliers / Instapill

Instapill

India 233 employees Updated 9 July 2026

Instapill is a finished-dose manufacturer based in India. It appears in 11 regulatory filings across 1 regulator, without an active US DMF or CEP on file. Its GMP standing is certified by US FDA, MHRA (UK) and EMA. Its most recent recorded inspection, by US FDA, closed on 13 September 2024 as VAI. Customs aggregates show $518K of exports covering 64 molecules to 3 destinations in 2026 so far.

0
active US DMFs
0
valid CEPs
3
registered plants 1 with an FDA FEI number
11
filings across 1 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
1 of 1 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 13 September 2024 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
BENGALURU SOUTH DISTRICT, India Not on file
Bengaluru, India 3014463103
Bengaluru Rural, India Not on file

Filings and GMP by regulator

Regulator Filings GMP certificates
EMA 11 1
US FDA None 1
MHRA (UK) None 1

Scale

Year Revenue Exports Destinations
2026 YTD Not reported $518K 3

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Instapill comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 13 September 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Customs aggregates
Export values, molecule and destination counts